{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:15:22Z","timestamp":1778148922438,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Technologies R&D Program of Guangdong Province","award":["2023B1111030003"],"award-info":[{"award-number":["2023B1111030003"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82241231"],"award-info":[{"award-number":["82241231"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82373307"],"award-info":[{"award-number":["82373307"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2024M753780"],"award-info":[{"award-number":["2024M753780"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515013214"],"award-info":[{"award-number":["2024A1515013214"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institutional funding of The First Affiliated Hospital of Sun Yat-sen University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01375-4","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:46:26Z","timestamp":1773845186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Organ-metastatic landscape delineates overall and site-specific immune-related adverse events of PD-L1 blockade in advanced NSCLC"],"prefix":"10.1038","volume":"10","author":[{"given":"Si-Heng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengli","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zekang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianming","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baixu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junchao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Cong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"1375_CR1","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073\u20134126 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1375_CR2","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1200\/JCO-24-02786","volume":"43","author":"NB Leighl","year":"2025","unstructured":"Leighl, N. B. et al. Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2024.3. J. Clin. Oncol. 43, e17\u2013e30 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1375_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101313","volume":"84","author":"YZ Wang","year":"2026","unstructured":"Wang, Y. Z. et al. Dissection of immunotherapeutic predictive versus prognostic transcriptional programs identifies SLC22A5-centric carnitine metabolism-driven resistance to anti-PD-(L)1 treatment in non-small cell lung cancer. Drug Resist Updat 84, 101313 (2026).","journal-title":"Drug Resist Updat"},{"key":"1375_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun, Q. et al. Immune checkpoint therapy for solid tumours: Clinical dilemmas and future trends. Signal Transduct. Target Ther. 8, 320 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1375_CR5","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma, P. et al. Immune checkpoint therapy-current perspectives and future directions. Cell 186, 1652\u20131669 (2023).","journal-title":"Cell"},{"key":"1375_CR6","doi-asserted-by":"publisher","first-page":"101215","DOI":"10.1016\/j.drup.2025.101215","volume":"81","author":"S Dong","year":"2025","unstructured":"Dong, S. et al. Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs. Drug Resist Updat 81, 101215 (2025).","journal-title":"Drug Resist Updat"},{"key":"1375_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ccell.2022.02.015","volume":"40","author":"S Goswami","year":"2022","unstructured":"Goswami, S. et al. A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell 40, 249\u2013251 (2022).","journal-title":"Cancer Cell"},{"key":"1375_CR8","doi-asserted-by":"publisher","first-page":"e008591","DOI":"10.1136\/jitc-2023-008591","volume":"12","author":"K Fletcher","year":"2024","unstructured":"Fletcher, K. & Johnson, D. B. Chronic immune-related adverse events arising from immune checkpoint inhibitors: An update. J. Immunother. Cancer. 12, e008591 (2024).","journal-title":"J. Immunother. Cancer."},{"key":"1375_CR9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1217\u20131238 (2022).","journal-title":"Ann. Oncol."},{"key":"1375_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson, J. A. et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 20, 387\u2013405 (2022).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"1375_CR11","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L. & Hansen, A. R. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann. Oncol. 28, 2377\u20132385 (2017).","journal-title":"Ann. Oncol."},{"key":"1375_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1909296","volume":"10","author":"SC Ma","year":"2021","unstructured":"Ma, S. C. et al. Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: Results from two randomized studies. Oncoimmunology 10, 1909296 (2021).","journal-title":"Oncoimmunology"},{"key":"1375_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2307\/2532740","volume":"48","author":"B Lausen","year":"1992","unstructured":"Lausen, B. & Schumacher, M. Maximally selected rank statistics. Biometrics 48, 73\u201385 (1992).","journal-title":"Biometrics"},{"key":"1375_CR14","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med 378, 2288\u20132301 (2018).","journal-title":"N. Engl. J. Med"},{"key":"1375_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West, H. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 924\u2013937 (2019).","journal-title":"Lancet Oncol."},{"key":"1375_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","volume":"16","author":"M Nishio","year":"2021","unstructured":"Nishio, M. et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: Results from the randomized phase 3 IMpower132 trial. J. Thorac. Oncol. 16, 653\u2013664 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1375_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1613","volume":"14","author":"X Lin","year":"2024","unstructured":"Lin, X. et al. Immune-related adverse events in non-small cell lung cancer: Occurrence, mechanisms and therapeutic strategies. Clin. Transl. Med. 14, e1613 (2024).","journal-title":"Clin. Transl. Med."},{"key":"1375_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00439","volume":"8","author":"C Kerepesi","year":"2024","unstructured":"Kerepesi, C. et al. Association of baseline tumor-specific neoantigens and CD8(+) T-cell infiltration with immune-related adverse events secondary to immune checkpoint inhibitors. JCO Precis Oncol. 8, e2300439 (2024).","journal-title":"JCO Precis Oncol."},{"key":"1375_CR19","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s43018-023-00572-5","volume":"4","author":"C Sung","year":"2023","unstructured":"Sung, C. et al. Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer. Nat. Cancer 4, 844\u2013859 (2023).","journal-title":"Nat. Cancer"},{"key":"1375_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03676-6","volume":"22","author":"ZX Rong","year":"2024","unstructured":"Rong, Z. X. et al. HLA diversity unveils susceptibility and organ-specific occurrence of second primary cancers: a prospective cohort study. BMC Med 22, 443 (2024).","journal-title":"BMC Med"},{"key":"1375_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02315-2","volume":"20","author":"SC Ma","year":"2022","unstructured":"Ma, S. C. et al. Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: Applicability from clinical trials to real-world practice. BMC Med 20, 120 (2022).","journal-title":"BMC Med"},{"key":"1375_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/cmi.2011.47","volume":"9","author":"E Zhao","year":"2012","unstructured":"Zhao, E. et al. Bone marrow and the control of immunity. Cell Mol. Immunol. 9, 11\u201319 (2012).","journal-title":"Cell Mol. Immunol."},{"key":"1375_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1136\/jcp.2003.013623","volume":"58","author":"N Nathoo","year":"2005","unstructured":"Nathoo, N., Chahlavi, A., Barnett, G. H. & Toms, S. A. Pathobiology of brain metastases. J. Clin. Pathol. 58, 237\u2013242 (2005).","journal-title":"J. Clin. Pathol."},{"key":"1375_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337\u2013341 (2015).","journal-title":"Nature"},{"key":"1375_CR25","doi-asserted-by":"publisher","first-page":"e011273","DOI":"10.1136\/jitc-2024-011273","volume":"13","author":"P Middha","year":"2025","unstructured":"Middha, P. et al. Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events. J. Immunother. Cancer. 13, e011273 (2025).","journal-title":"J. Immunother. Cancer."},{"key":"1375_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02713-6","volume":"21","author":"XJ Guo","year":"2023","unstructured":"Guo, X. J. et al. Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation. BMC Med. 21, 6 (2023).","journal-title":"BMC Med."},{"key":"1375_CR27","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamaoncol.2021.0729","volume":"7","author":"B Zhang","year":"2021","unstructured":"Zhang, B., Nie, W. & Han, B. Immune-related adverse events and efficacy-the more it hurts, the better it works? JAMA Oncol. 7, 944\u2013945 (2021).","journal-title":"JAMA Oncol."},{"key":"1375_CR28","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.2147\/CMAR.S310331","volume":"13","author":"WJ Yin","year":"2021","unstructured":"Yin, W. J., Ma, S. C., Dong, Z. Y., Xu, M. & Mao, W. Efficacy and treatment strategies in advanced cancers with liver metastasis receiving atezolizumab therapy. Cancer Manag. Res. 13, 4541\u20134551 (2021).","journal-title":"Cancer Manag. Res."},{"key":"1375_CR29","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1007\/s00432-022-04340-3","volume":"149","author":"A Miah","year":"2023","unstructured":"Miah, A. et al. Immune checkpoint inhibitor-induced hepatitis injury: Risk factors, outcomes, and impact on survival. J. Cancer Res. Clin. Oncol. 149, 2235\u20132242 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1375_CR30","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem, J. E. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 19, 1579\u20131589 (2018).","journal-title":"Lancet Oncol."},{"key":"1375_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain, L., Diem, S. & Larkin, J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat. Rev. 44, 51\u201360 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"1375_CR32","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1210\/clinem\/dgad260","volume":"108","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q., Jiao, X. & Lai, X. Clinical characters and influence factors of immune checkpoint inhibitor-related thyroid dysfunction. J. Clin. Endocrinol. Metab. 108, 2916\u20132923 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1375_CR33","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","volume":"77","author":"DY Oh","year":"2017","unstructured":"Oh, D. Y. et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res 77, 1322\u20131330 (2017).","journal-title":"Cancer Res"},{"key":"1375_CR34","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","volume":"5","author":"F Berner","year":"2019","unstructured":"Berner, F. et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 5, 1043\u20131047 (2019).","journal-title":"JAMA Oncol."},{"key":"1375_CR35","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(08)70201-8","volume":"9","author":"IJ Fidler","year":"2008","unstructured":"Fidler, I. J. & Poste, G. The \u201cseed and soil\u201d hypothesis revisited. Lancet Oncol. 9, 808 (2008).","journal-title":"Lancet Oncol."},{"key":"1375_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","volume":"133","author":"S Paget","year":"1889","unstructured":"Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 133, 571\u2013573 (1889).","journal-title":"Lancet"},{"key":"1375_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","volume":"120","author":"S Khan","year":"2019","unstructured":"Khan, S. et al. Immune dysregulation in cancer patients developing immune-related adverse events. Br. J. Cancer 120, 63\u201368 (2019).","journal-title":"Br. J. Cancer"},{"key":"1375_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.lungcan.2019.03.020","volume":"132","author":"J Oyanagi","year":"2019","unstructured":"Oyanagi, J. et al. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. Lung Cancer 132, 107\u2013113 (2019).","journal-title":"Lung Cancer"},{"key":"1375_CR39","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1158\/0008-5472.CAN-23-2941","volume":"84","author":"JR Lin","year":"2024","unstructured":"Lin, J. R. et al. Regular use of aspirin and statins reduces the risk of cancer in individuals with systemic inflammatory diseases. Cancer Res 84, 1889\u20131897 (2024).","journal-title":"Cancer Res"},{"key":"1375_CR40","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","volume":"24","author":"A Pavan","year":"2019","unstructured":"Pavan, A. et al. Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Oncologist 24, 1128\u20131136 (2019).","journal-title":"Oncologist"},{"key":"1375_CR41","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1007\/s00262-021-02996-3","volume":"70","author":"E Suazo-Zepeda","year":"2021","unstructured":"Suazo-Zepeda, E. et al. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: A systematic review and meta-analysis. Cancer Immunol. Immunother. 70, 3069\u20133080 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"1375_CR42","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018306","volume":"9","author":"ZD Drobni","year":"2020","unstructured":"Drobni, Z. D. et al. Decreased absolute lymphocyte count and increased neutrophil\/lymphocyte ratio with immune checkpoint inhibitor-associated myocarditis. J. Am. Heart Assoc. 9, e018306 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"1375_CR43","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","volume":"24","author":"A Cortellini","year":"2019","unstructured":"Cortellini, A. et al. Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: A real-world transverse study. Oncologist 24, e327\u2013e337 (2019).","journal-title":"Oncologist"},{"key":"1375_CR44","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","volume":"10","author":"L Marthey","year":"2016","unstructured":"Marthey, L. et al. Cancer Immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J. Crohns Colitis 10, 395\u2013401 (2016).","journal-title":"J. Crohns Colitis"},{"key":"1375_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255\u2013265 (2017).","journal-title":"Lancet"},{"key":"1375_CR46","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837\u20131846 (2016).","journal-title":"Lancet"},{"key":"1375_CR47","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","volume":"35","author":"S Peters","year":"2017","unstructured":"Peters, S. et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J. Clin. Oncol. 35, 2781\u20132789 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1375_CR48","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst, R. S. et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N. Engl. J. Med 383, 1328\u20131339 (2020).","journal-title":"N. Engl. J. Med"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01375-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01375-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01375-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:04:35Z","timestamp":1778148275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01375-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1375"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01375-4","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}